HRMY Harmony Biosciences Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HRMY

Price (delayed)

$31.57

Market cap

$1.79B

P/E Ratio

13.43

Dividend/share

N/A

EPS

$2.35

Enterprise value

$1.65B

Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves ...

Highlights
The company's revenue rose by 31% YoY and by 6% QoQ
The gross profit has grown by 28% YoY and by 6% from the previous quarter
The quick ratio has contracted by 37% YoY but it has grown by 12% from the previous quarter
Harmony Biosciences Holdings's net income has decreased by 27% YoY but it has increased by 7% from the previous quarter
The gross margin has contracted by 2.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.harmonybiosciences.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of HRMY
Market
Shares outstanding
56.79M
Market cap
$1.79B
Enterprise value
$1.65B
Valuations
Price to earnings (P/E)
13.43
Price to book (P/B)
3.48
Price to sales (P/S)
2.9
EV/EBIT
7.74
EV/EBITDA
6.95
EV/Sales
2.67
Earnings
Revenue
$617.51M
EBIT
$213.05M
EBITDA
$237.47M
Free cash flow
$207.65M
Per share
EPS
$2.35
Free cash flow per share
$3.66
Book value per share
$9.08
Revenue per share
$10.88
TBVPS
$12.61
Balance sheet
Total assets
$846.99M
Total liabilities
$331.59M
Debt
$190M
Equity
$515.39M
Working capital
$325.25M
Liquidity
Debt to equity
0.37
Current ratio
3.11
Quick ratio
2.93
Net debt/EBITDA
-0.6
Margins
EBITDA margin
38.5%
Gross margin
79.3%
Net margin
22.3%
Operating margin
33%
Efficiency
Return on assets
17.2%
Return on equity
28.3%
Return on invested capital
53.3%
Return on capital employed
30.8%
Return on sales
34.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRMY stock price

How has the Harmony Biosciences Holdings stock price performed over time
Intraday
-0.38%
1 week
7.67%
1 month
-0.41%
1 year
-12.28%
YTD
-2.26%
QTD
-5.99%

Financial performance

How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$617.51M
Gross profit
$489.57M
Operating income
$203.64M
Net income
$137.7M
Gross margin
79.3%
Net margin
22.3%
The operating income has soared by 53% YoY and by 6% from the previous quarter
The net margin has contracted by 45% YoY
The company's revenue rose by 31% YoY and by 6% QoQ
The gross profit has grown by 28% YoY and by 6% from the previous quarter

Growth

What is Harmony Biosciences Holdings's growth rate over time

Valuation

What is Harmony Biosciences Holdings stock price valuation
HRMY P/E details
P/E
13.43
P/B
3.48
P/S
2.9
EV/EBIT
7.74
EV/EBITDA
6.95
EV/Sales
2.67
Harmony Biosciences Holdings's EPS has decreased by 26% YoY but it has increased by 8% QoQ
Harmony Biosciences Holdings's equity has increased by 16% YoY and by 10% from the previous quarter
The stock's price to book (P/B) is 13% less than its last 4 quarters average of 4.0
The company's revenue rose by 31% YoY and by 6% QoQ
HRMY's P/S is 19% below its last 4 quarters average of 3.6

Efficiency

How efficient is Harmony Biosciences Holdings business performance
The ROE is down by 46% YoY but it is up by 2.9% from the previous quarter
HRMY's return on assets is down by 42% year-on-year but it is up by 2.4% since the previous quarter
HRMY's return on invested capital is up by 23% year-on-year and by 5% since the previous quarter
Harmony Biosciences Holdings's return on sales has increased by 17% YoY

Dividends

What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRMY.

Financial health

How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is 155% greater than its total liabilities
The quick ratio has contracted by 37% YoY but it has grown by 12% from the previous quarter
The current ratio has contracted by 37% YoY but it has grown by 13% from the previous quarter
The debt is 63% less than the equity
Harmony Biosciences Holdings's equity has increased by 16% YoY and by 10% from the previous quarter
The debt to equity has declined by 14% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.